AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win
After recently discontinuing R&D for Truqap in triple-negative breast cancer, AstraZeneca has some good news on its kinase inhibitor in a different indication.
The UK …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.